Swiss Wellness Biotech Brand Timeline Secures Financing from L’Oréal and Nestlé

Timeline, a consumer health biotech company developing solutions for healthy aging and longevity, raised $66 million in a Series D financing round.
 
This marks a significant milestone for the company and includes strategic investments from L’Oréal and Nestlé.
 
The financing round was led by BOLD (Business Opportunities for L’Oréal Development), L'Oréal Groupe’s strategic innovation venture capital fund

Mitopure, Timeline's proprietary technology, is backed by more tgan 15 years of research and is clinically proven to target a key cellular longevity pathway, by recycling and renewing mitochondria.
 
“This strategic collaboration reflects the breakthrough multidimensional approach that we've always believed is necessary to make meaningful advancements for longevity and health span,” said Patrick Aebischer, co-founder and chairman of Timeline. “I want to thank L’Oréal, Nestlé and our longstanding investors for their commitment to longevity solutions rooted in the highest level of science.”
 
“Longevity is about living healthier for longer and L’Oréal has been working for a decade to understand and anticipate what this could mean for beauty,” said Barbara Lavernos, deputy chief executive officer and in charge of research, innovation and technology, L’Oréal. “Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analyzing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”